Lexapro Patent Challenge NEW YORK, April 28 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) reported that today the U.S. District Court for the District of Delaware has rescheduled opening arguments from May 9, 2005 to December 5, 2005 for the trial related to patent litigation regarding the SSRI antidepressant Lexapro(R). Forest Laboratories, Inc., Forest Laboratories Ireland Ltd. and H. Lundbeck A/S are plaintiffs with co-defendants being Ivax Pharmaceuticals, Inc / Cipla Ltd. and Alphapharm Pty Ltd. The reason for the delay is that defendant Alphapharm Pty Ltd. has alleged that H. Lundbeck A/S destroyed relevant evidence. In response the Court will appoint a Special Master to investigate the matter prior to opening arguments. Forest remains confident in the strength of the Lexapro patent. (Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) About Forest Laboratories and Its Products Forest Laboratories' growing line of products includes: Lexapro(R) (escitalopram oxalate), an SSRI antidepressant indicated for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder in adults; Namenda(R) (memantine HCl), an N-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker indicated for the treatment of hypertension; Benicar* HCT(R) (olmesartan medoxomil hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product indicated for the second-line treatment of hypertension; Campral(R)* (acamprosate calcium), a glutamate receptor modulator, indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation in combination with psychosocial support; and Combunox(TM) (Oxycodone HCl and Ibuprofen), an opioid and NSAID combination indicated for the short-term management of acute, moderate to severe pain. Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products and the risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2004, and on form 10-Q for the periods ended June 30, September 30, and December 31, 2004. *Benicar is a registered trademark of Sankyo Pharma, Inc., and Campral is a registered trademark under license from Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany. SOURCE Forest Laboratories, Inc. CONTACT: Charles E. Triano, Vice President-Investor Relations of Forest Laboratories, Inc., +1-212-224-6714 -0- Apr/28/2005 20:40 GMT
Forest Laboratories Announces Court Sets New Trial Date for
Press spacebar to pause and continue. Press esc to stop.